<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01335633</url>
  </required_header>
  <id_info>
    <org_study_id>691-11 PVCE</org_study_id>
    <nct_id>NCT01335633</nct_id>
  </id_info>
  <brief_title>Psychometric Validation of Cognitive Endpoints</brief_title>
  <official_title>Psychometric Validation of Cognitive Endpoints</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kessler Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kessler Foundation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will entail cognitive assessment of a single cohort of patients with Multiple&#xD;
      Sclerosis. Each subject will be assessed twice, approximately 45 days apart. There will be no&#xD;
      intervention or control group. Each participant will have a caregiver capable of responding&#xD;
      to a brief report of observations regarding neuropsychological skills and abilities in the&#xD;
      patient.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Actual">60</enrollment>
  <condition>Multiple Sclerosis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals with Multiple Sclerosis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 to 65 years old (inclusive).&#xD;
&#xD;
          -  History of Relapsing-Remitting or Secondary Progressive Multiple Sclerosis&#xD;
&#xD;
          -  Physically able to see the testing materials and complete the tests&#xD;
&#xD;
          -  Have a family member or caregiver who is capable of consent and willing to complete&#xD;
             the MSNQ-Informant questionnaire.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A history of treated or untreated severe mental illness or diagnosis of major&#xD;
             depression prior to MS onset.&#xD;
&#xD;
          -  Untreated major depression or untreated anxiety disorder.&#xD;
&#xD;
          -  History of Attention Deficit/Hyperactivity Disorder, Developmental Learning - Disorder&#xD;
             including Mental Retardation.&#xD;
&#xD;
          -  History of traumatic brain injury with intracranial bleed, stroke, Alzheimer's&#xD;
             disease, Parkinson's disease, Motor Coordination Disorder or other neurologic illness.&#xD;
             I understand that if the Investigator believes this would interfere with successful&#xD;
             completion of the protocol, I will be excluded.&#xD;
&#xD;
          -  A clinically significant relapse within the past 2 months. I have had a serious&#xD;
             infection (e.g., pneumonia, septicemia) within the 2 month.&#xD;
&#xD;
          -  History of drug or alcohol abuse (as defined by the Investigator) within 1 year prior&#xD;
             to Study Day 1.&#xD;
&#xD;
          -  Active bacterial or viral infection.&#xD;
&#xD;
          -  Use of marijuana within 2 months prior to Study Day 1or at any time during the study&#xD;
&#xD;
          -  Alcohol consumption within 24 hours of either test session.&#xD;
&#xD;
          -  Unable to comply with study requirements.&#xD;
&#xD;
          -  Expected survival time of less than 3 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John DeLuca, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kessler Foundation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Holy Name Hospital Multiple Sclerosis Center</name>
      <address>
        <city>Teaneck</city>
        <state>New Jersey</state>
        <zip>07666</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kessler Foundation</name>
      <address>
        <city>West Orange</city>
        <state>New Jersey</state>
        <zip>07052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University at Buffalo</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lauren S. Caruso</name>
      <address>
        <city>White Plains</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <study_first_submitted>April 13, 2011</study_first_submitted>
  <study_first_submitted_qc>April 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2011</study_first_posted>
  <last_update_submitted>May 1, 2012</last_update_submitted>
  <last_update_submitted_qc>May 1, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 3, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kessler Foundation</investigator_affiliation>
    <investigator_full_name>John DeLuca</investigator_full_name>
    <investigator_title>Vice President of Research</investigator_title>
  </responsible_party>
  <keyword>MS</keyword>
  <keyword>Neuropsychological tests</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

